Medable launched its Agentic Accelerator Program to help life sciences companies deploy agentic AI in clinical development. The offering includes onboarding, integration support, governance, and change management, and is designed to accelerate “time-to-value” for sponsors and CROs using Medable’s Agent Studio platform. On the tooling side, Bio-Techne and Refeyn partnered with Refeyn to deliver an integrated workflow combining icIEF fractionation (MauriceFlex) with TwoMP mass photometry for bispecific antibody and biosimilar characterization. The workflow targets charge and size/aggregation mapping in a single pipeline intended to reduce sample requirements and development risk. Together, the announcements point to a near-term convergence of AI-enabled operational scaling with high-resolution characterization workflows. For biotech teams, faster integration and better analytics are increasingly viewed as prerequisites for managing clinical complexity and manufacturing heterogeneity.